Vertex Pharmaceuticals Logo

Email this page: News Release

New England Journal of Medicine Publishes PROVE 3 Trial Showing Telaprevir-Based Regimens Significantly Increased Sustained Viral Response (SVR) Rates in Patients Who Did Not Achieve SVR with Prior HCV Therapy

For security reasons, registration is required before you can use this feature.
* Indicates required field